Collectively, these results provide a novel foundation for future investigations
By inhibiting NNMT, 5-Amino-1MQ appears to improve how the body handles glucose
What they found: No serious adverse events triggered by AOD-9604 The most frequent side effects: headache (~5 %), occasional fatigue, at the same frequency as placebo No changes in IGF-1 levels, glycemia, blood pressure, heart rate No signals of cardiovascular, hepatic or renal toxicity Safety profile comparable to placebo Why it matters: From a safety perspective, AOD-9604 is one of the safest peptides in the clinical registry
Treatment The injection is quick, and most people feel little to no pain
For in vitro studies, it is typically dissolved in DMSO or aqueous buffer depending on the experimental protocol
In this case the dose for intramuscular injection is typically 100 to 1,000 mcg every day or alternate day, for one to two weeks